The Top 3 Vaccine Stocks to Consider

The world is desperate for a vaccine.

At the moment, there are 29.6 million global cases, with 936,001 deaths.

In the U.S., there are 6.6 million cases. In India, it’s up to 5.02 million.  In Brazil, 4.3 million.  In Russia, 1.07 million.  In Peru, there are 738,020.  And in Colombia, 728,590.

With no vaccine to speak of, the world is still at a standstill.  

However, we may be nearing a solution in the next few months. 

Pfizer (PFE) and BioNTech (BNTX)

For one, Pfizer (PFE) CEO Albert Bourla just said there’s a “good chance” the company will know if its vaccine works by the end of October 2020.

The CEO told Face the Nation, “We started already manufacturing and we have already manufactured hundreds of thousands of doses, so just in case we have a good study readout, conclusive and FDA, plus the advisory committee feels comfortable that we will be ready.”

The company, along with BioNTech (BNTX) has already begun enrolling 30,000 people in its Phase 3 vaccine trial.  However, it’s now looking to expand that enrollment to 40,000, as it attempts to expand to far more vulnerable populations.

Eli Lilly (LLY)

Eli Lilly is higher on news it’s COVID-19 treatment reduced the hospitalization rate.  

“The U.S. drug maker said it tested three different doses of LY-CoV555 against a placebo in a trial enrolling roughly 450 patients. The middle dose of 2,800 mg met the trial’s target of significantly reducing the presence of SARS-CoV-2 after 11 days,” said CNBC.